Company intelligence / Profile preview
Okogen
Delaware, United Statesokogen.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Okogen is conducting clinical trials for its lead product as a treatment for all forms of acute infectious conjunctivitis. The company initiated a Phase 2 clinical trial for OKG-0301 to assess safety and efficacy, with top line results expected in early 2020. More recently, they submitted a regulatory application to CDSCO in India for a Phase IIb clinical trial called The Emerald Study[5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (antiviral, antibacterial, ocular decongestant)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Okogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Okogen.